The withdrawal of tricyclic antidepressants produces symptoms characteristic of cholinergic overdrive states. The authors previously proposed that these states are the consequence of the pharmacological induction of cholinergic system supersensitivity by chronic treatment with antidepressants, combined with a reduction in the plasma level of a competitive muscarinic receptor antagonist when the dose of a tricyclic is decreased. This is consistent with the facts that all tricyclic antidepressants are antimuscarinic agents and that classical antimuscarinic compounds, such as scopolamine, up-regulate and supersensitize muscarinic cholinergic systems. The authors present evidence that chronic treatment with amitriptyline supersensitizes a central cholinergic mechanism. Core body temperature is subject to influence by a central (hypothalamic) muscarinic mechanism, which is rendered supersensitive to cholinomimetic challenge by treatment with scopolamine. The authors telemetrically measured the hypothermic responses of adult male rats to various doses of the muscarinic agonist oxotremorine before and in the course of chronic treatment with amitriptyline. Treatment with amitriptyline resulted in marked enhancement of the cholinomimetic-induced hypothermia. Methylscopolamine nitrate, a peripherally active antimuscarinic agent, did not block the hypothermic response to oxotremorine, whereas scopolamine, a centrally active antimuscarinic compound, did. This study indicates that the chronic administration of amitriptyline can produce supersensitivity of a central muscarinic cholinergic mechanism. Clinical and theoretical implications of this finding are discussed.
Introduction
Many of the symptoms that commonly follow the discontinuation of tricyclic antidepressants (TCAs) suggest withdrawal-induced cholinergic overdrive (Dilsaver et al. 1983a; Dilsaver and Greden 1984) . Evidence supporting this includes observations that (1) anticholinesterases produce similar symptoms (Dilsaver 1986a,b) ; (2) TCA withdrawal symptoms respond to antimuscarinic agents (Dilsaver et al. 1983b) ; (3) TCAs competitively displace muscarinic acetylcholine receptor (mAchR) radioligands in binding experiments (Snyder and Yamamura 1977) and produce physiological and biochemical effects indic-ative of mAchR blockade (Atkinson and Landinsky 1972; Richelson and Dininetz-Romero 1977; Blackwell et al. 1978; Szabadi et al. 1980) ; and (4) anticholinergic agents upregulate and supersensitize cholinergic networks in rodents (Dilsaver 1986~) .
Body temperature is subject to regulation by central (hypothalamic) cholinergic mechanisms (Lomax et al. 1964; Lomax and Jenden 1966) , which are supersensitized by mAchR blockade in rats (Jaffe and Sharpless 1968; Friedman et al. 1969) . We tested the hypothesis that chronic treatment with a TCA produces cholinergic system supersensitivity by measuring the hypothermic response to the centrally active cholinomimetic oxotremorine (0X0), before and after chronic treatment with amitriptyline (AMI).
Methods

Temperature Measurement
Thermosensors (Mini-Mitter Co., Sun River, OR) were surgically implanted into the peritoneal cavity of rats. These devices emit Hertzian waves at a rate proportional to temperature. A transistor radio set to an AM frequency served as a receiver. Time to emit 25 sounds or "clicks" was measured using a digital display stopwatch. This measure was converted to temperature using a linear regression equation that was derived by measuring the emission rate of the thermosensors at three temperatures in a temperaturecontrolled water bath. This procedure is sensitive to a 0. 1°C change in temperature (ToccoBradley et al. 1985) .
Oxotremorine Challenge
All OX0 challenges were conducted at the same time of day, 12 hr after the evening dose of AMI. Methylscopolamine nitrate (1 mg/kg, i.p.) was administered 30 min prior to the i.p. injection of OX0 to block its peripheral effects. Temperature (i.e., time to the 25th "click") was measured immediately prior to and 30 min after injecting methylscopolamine, which alone did not affect temperature in 31 trials. Baseline temperature was defined as the average of the pre-and postmethylscopolamine nitrate measurements. OX0 was given immediately after the 30-min postmethylscopolamine nitrate temperature measurement. Temperature was recorded every 15 min for 120 min. Pharmaceuticals 0X0, methylscopolamine nitrate, scopolamine hydrobromide, and amitriptyline hydrochloride were purchased from Sigma Chemical Company (St. Louis, MO). Doses of OX0 refer to the base. Doses of the other drugs were expressed as the salt form. All drugs were given intraperitoneally on a milligram per kilogram basis.
Experimental Design
Experiment 1. Figure 1 presents the course of Experiment 1. The experiment was divided into four phases. In Phase I (implantation), thermosensors were implanted in 15 male adult Sprague-Dawley rats, and they were allowed 5 days to recover. During Phase II, the baseline hypothermic response to OX0 (0.05, 0.10, 0.25, 1.0, and 2.5 mg/kg) was recorded in three groups of five animals each, as shown in Figure 1 Phase III, animals were treated with AM1 (10 mgkg, i.p., twice daily) for 16 days. The animals were rechallenged with 0X0, 0.05, 0.1, or 0.25 mg/kg, between days 12 and 16 of treatment with AMI. These data were compared to the pre-AM1 response to various doses of 0X0. In Phase IV, 9 animals received AM1 (10 mg/kg) for an additional 10 days. They then received AMI, 20 mg/kg for 5 more days prior to receiving a challenge with OX0 at 0.125 mg/kg. Experiment 2. Two groups of animals were challenged with 0X0, 1 mg/kg, i.p., prior to starting a course of AMI, 10 mg/kg twice daily for 2 days and 15 mgkg twice daily for 5 days (n = 5), or saline (n = 4). The maximum hypothermic response and decrease in temperature over time at baseline and after treatment were compared within and between groups.
Experiment 3. Eleven animals in Experiment 1 received AM1 10 mgkg, i.p., for 17 days. These animals then received scopolamine hydrobromide, 2 mgkg, i.p., as a pretreatment in lieu of methylscopolamine nitrate in order to assess whether a peripheral or central mechanism underlies 0X0-induced hypothermia.
Statistical Analysis
Data were analyzed using (1) Analysis of Variance (ANOVA) with repeated measures to assess the significance of differences between phases due to a drug effect (i.e., preand posttreatment), (2) two-sample r-tests for comparing sample means, and (3) paired t-tests to assess the significance of changes in the mean maximum hypothermic response and the mean hypothermic response over all eight time points within a sample, before and after the chronic administration of AMI. Calculation of confidence intervals was used to determine whether or not the mean change in core temperature produced by OX0 (2.5 mg/kg) after pretreatment with scopolamine hydrobromide in Experiment 3 differed significantly from the condition of pretreatment with methylscopolamine nitrate at specific points in time after the injection of OX0 and whether or not the mean effect (average response to OX0 over all eight time points) differed.
Results
Experiment 1
OX0 produced dose-dependent hypothermia prior to AM1 treatment. This was evidenced by significant differences in the magnitude of the hypothermic responses over time to 0X0: 0.1 versus 1.0 mg/kg, p < 0.01; 1 mg/kg versus 2.5 mg/kg, p < 0.05 (ANOVA with repeated measures). Table 1 summarizes the responsiveness to OX0 at 0.05, 0.10, and 0.25 mg/kg before and after treatment with AMI, 10 mg/kg, i.p., twice daily for 12-16 days. Table 2 presents the corresponding data on the responsiveness to OX0 at 1 .O and 2.5 mg/kg, i.p. The 9 animals that were rechallenged with OX0 at 0.05 mg/kg after 12-16 days of treatment with AM1 exhibited significant enhancement of the hypothermic response (p < 0.05). The 10 animals rechallenged with OX0 at 0.1 mg/kg after 12-16 days of AM1 treatment showed enhancement of the hypothermic response (p < 0.02). OX0 at 0.25 mg/kg also produced increased hypothermia relative to the pretreatment phase (p < 0.0001, n = 11) posttreatment. Figure 2 pictorially presents the difference in the hypothermic response to OX0 at 0.10 mg/kg before and after treatment with AMI. Animals treated with AM1 (10 mg/kg for 26 days, followed by 20 m&g for 5 additional days) had a mean maximum decrease in temperature of 1.5 1 & 0.19"C (SEM) when given OX0 at 0.125 mg/kg. Change in temperature over time in response to OX0 at 0.125 mg/kg was actually greater after treatment with AM1 than it was in response to OX0 at 2.5 mg/kg at baseline (p < 0.02, ANOVA with repeated measures). Table 3 summarizes these data, and Figure 3 illustrates the general relationship between dose of OX0 and hypothermic response before and after treatment with AMI.
Experiment 2
The maximum decrease in temperature and change in temperature over time did not change in the saline-treated sample (n = 4). The AMI-treated sample demonstrated a significantly greater maximum decrease in temperature [1.57 -+ 0.15"C @EM) versus 0.64 ? O.l2"C, p < 0.05, two-sample t-test] compared to the saline-treated sample after, but not before, the 7 days of treatment. Furthermore, the AM1 group (n = 5) exhibited a significant increase in its maximum hypothermic response of 1.2 f. 0.34"C (SEM) (p < 0.05, paired t-test) and trends toward a significant decrease in temperature over all 8 points in time (p < 0.06, ANOVA with repeated measures) compared to its pretreatment phase. The results of this experiment are depicted in Figure 4 .
Experiment 3
Scopolamine markedly blunted the hypothermic effects of 0X0. The mean maximal decrease in temperature in response to OX0 at 2.5 mg/kg after pretreatment with scopolamine (2 mg/kg, i.p.) was 0.17 2 0.08"C @EM) (n = 11) in animals that were treated with AMI at 10 mgkg, i.p., twice daily for 17 days (NS, 95% confidence limits = + 0.01 to -0.35"(J), and the average change in temperature over time (i.e., the mean of all 11 animals over all 8 points) was 0.11 k 0.03"C (SEM) (99% confidence limits = -0.01 to -0.21"C) compared to -0.54 + 11°C (SEM) (99% confidence limits = -0.213 to -0.87"C) when treated with methylscopolamine. Thus, the difference in responsiveness to OX0 at 2.5 mgkg under the condition of pretreatment with scopolamine and methylscopolamine differed at the 0.01 level. The results of this experiment are presented in Figure 5 .
Discussion
Maximum decrease in core temperature, changes in temperature over time, and change in core temperature at 8 points in time after the injection of OX0 were used as dependent variables in evaluating the effects of chronic treatment with AM1 on a muscarinic cho-S.C. Dilsaver et al. prior to and after treatment with AM1 (10 mg/kg, i.p. twice daily for 12-16 days). The mean difference is significant atp < 0.02. Furthermore, there was a significant difference in the direction predicted by the hypothesis that AMI enhances sensitivity to the hypothermic effects at 7 of 8 points in time.
linergic system. The data indicate that (1) saline injections do not alter the hypothermic response to 0X0; (2) treatment with AM1 enhanced the hypothermic response to OX0 (0.05, 0.1, and 0.25 mg/kg) relative to the pretreatment baseline; (3) scopolamine (2.0 mg/kg), but not methylscopolamine nitrate, blocks the OX0 (2.5 mg/kg) induced temperature decrease, implicating a central cholinergic mechanism; and (4) AM1 induces central cholinergic system supersensitivity.
These results support the hypothesis that cholinergic overdrive is involved in the pathophysiology of some TCA withdrawal phenomena. The observation that 21 days of treatment with desipramine produces supersensitivity of the iris to pilocarpine (i.e., results in a greater miotic response) relative to the This table compares the mean hypothermic response at each of 8 time points atkr the injection of OX0 at 2.5 me/Le at baseline and 0.125 mg&g after chronic (31 days) treatment with AMI. All animals received AM1 (10 mgkg, i.p.) twice daily for 26 days, followed by 20 mgntg wss a more potent inducer of hypothermia sfter chronic treatment than was 2.5 mg/kg at baseliw. pretreatment baseline in normal human subjects also supports this conclusion (Dilsaver and Greden 1983) . Nomura et al. (1982a,b) reported corroborative findings in rat myocardium using desipramine at 10 mg/kg twice daily for 10 days. This regimen was associated with enhancement of the negative inotropic effects and an increase in the acetylcholine-mediated augmentation of the activity of omithine carboxylase. These investigators also found an increased density of mAchR radioligand binding sites in this preparation following treatment with DMI. Rehavi et al. (1980) and Goldman and Erickson (1983) have similarly documented that 10-21 days of treatment with AM1 results in up-regulation of mAchRs in mouse and rat brain, respectively.
An array of evidence suggests that the pathophysiology of depression involves supersensitivity of central muscarinic cholinergic mechanisms (Dilsaver 1986b) . Pharmacological agents that supersensitize cholinergic neurons may be useful in modeling aspects of the pathophysiology of depressive disorders. Measures useful in describing the neurobiology of these illnesses can be classified as being (1) phenomenological or behavioral, (2) physiological, (3) biochemical, and (4) receptor binding variables (Dilsaver 1986a) . Cholinergic manipulations change variables in each of these classes. Many of these alterations are consistent with the hypothesis that hyperactivity or supersensitivity of cholinergic systems are involved in the pathogenesis of depressive disorders. For instance, administration of scopolamine to normal human subjects for three consecutive mornings resulted in shortened REM latency and increased REM density on the night after the dose was held on the fourth morning. The polysomnograms of these subjects were indistinguishable from those of patients with primary depression. Another phenomenon that may be related to the capacity of TCAs to render cholinergic systems supersensitive is the significant increase in the postdexamethasone plasma cortisol concentration and frequency of positive Dexamethasone Suppression Test (DST) results during a 14&y withdrawal phase (Dilsaver and Greden 1985) . Finally, Kelwala (1984) reported that depressed patients demonstrate increased miosis in response to pilocarpine compared to normal and nonaffectively ill psychiatric control subjects. The capacity of desipramine to produce this effect in depressed patients (Dilsaver and Greden 1983) may be another illustration of the way in which antimuscarinic agents, including TCAs, may be useful in modeling aspects of the pathophysiology of depression related to supersensitivity of the cholinergic systems.
In conclusion, treatment with AMI resulted in supersensitization of a central cholinergic mechanism involved in thermoregulation. This is consistent with the hypotheses that TCA withdrawal symptoms may be due to withdrawal-induced cholinergic overdrive (Dilsaver Figure 4. The change in the thermic response to OX0 (1 mgkg, i.p.) in rats receiving twice daily i.p. injections of saline (n = 4) or AMI (15 mgkg) (n = 5). Both samples were challenged with OX0 prior to and after saline or AMI administration.
The thermic response at a given time point on a particular day is derived from the formula: (core hody temperature at that point in time) -(core hody temperature prior to the injection of OX0 on that day). Change in the thermic response at a given point after treatment with saline or AM1 is given by the formula: (thermic response after treatment) -(thermic response prior to treatment). The thermic response of the sample treated with saline did not change significantly, whereas that of the AMI-treated group did. et al. 1983a; Dilsaver and Greden 1984) , and TCAs may be useful for approximating or modeling those aspects of the pathophysiology of depressive disorders related to upregulation and supersensitivity of cholinergic systems (Dilsaver 1986a-c) . Figure 5 . The thermic response of 11 animals to OX0 (2.5 mg/kg) in the presence and absence of scopolamine (2 mg/kg, i.p.). Pretreatment with scopolamine was associated with significant blunting of the hypothermic response (p < 0.01).
